CompletedPhase 2NCT01140737
A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Principal Investigator
- Penella Woll, BMedSciWeston Park Hospital, Sheffield, UK
- Intervention
- Axitinib(drug)
- Enrollment
- 145 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2010 – 2019
Study locations (13)
- Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom
- Western General Hospital, Edinburgh, Scotland, United Kingdom
- Bristol Haematology & Oncology Centre, Bristol, United Kingdom
- St. James's Hospital, Leeds, United Kingdom
- Royal Marsden Hospital, London, United Kingdom
- Royal Marsden, London, United Kingdom
- University College London Hospitals, London, United Kingdom
- Christies, Manchester, United Kingdom
- Clatterbridge Centre for Oncology, Metropolitan Borough of Wirral, United Kingdom
- Nottingham City Hospital, Nottingham, United Kingdom
- Churchill Hospital, Oxford, United Kingdom
- Penella Woll, Sheffield, United Kingdom
- Southampton General Hospital, Southampton, United Kingdom
Collaborators
University of Birmingham · Cancer Research UK · Pfizer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01140737 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive